NAV
Closed to all investors.
×Also available as an ETF (starting at the price of one share) and at a lower cost as an Admiral™ Shares mutual fund
Management style
Asset class
Category
Risk / reward scale
—
Investment minimum
as of
NAV price
—
CUSIP | 922042791 |
|---|---|
Management style | Index |
Asset class | — |
Category | — |
Inception date | 03/08/2007 |
Fund Number | 0770 |
YTD returns
as of 04/04/2025
Vanguard Equity Index Group
as of —
Recent returns
Average annual
| Month-end | 3-Month total | YTD | 1-yr | 3-yr | 5-yr | 10-yr | Since inception 03/08/2007 | |
|---|---|---|---|---|---|---|---|---|
VFWIX | — | — | — | — | — | — | — | — |
| -0.05% | 4.97% | 4.97% | 6.13% | 4.64% | 11.33% | 5.31% | — |
This information is temporarily unavailable.
as of 12/31/2018
| Year | Capital return by NAV | Income return by NAV | Total return by NAV | |
|---|---|---|---|---|
| 2018 | -16.47% | 2.44% | -14.03% | -14.13% |
| 2017 | 23.69% | 3.38% | 27.08% | 27.11% |
| 2016 | 1.69% | 2.98% | 4.67% | 4.80% |
| 2015 | -7.25% | 2.47% | -4.78% | -4.72% |
| 2014 | -7.18% | 2.97% | -4.21% | -3.31% |
| 2013 | 11.23% | 3.11% | 14.34% | 15.31% |
| 2012 | 15.04% | 3.32% | 18.35% | 17.48% |
| 2011 | -16.88% | 2.47% | -14.41% | -13.76% |
| 2010 | 9.41% | 2.28% | 11.69% | 11.65% |
This information is temporarily unavailable.
VFWIX
0.20%
Average expense ratio of similar funds2
—
This information is temporararily unavailable
Purchase fee
None
Fund family redemption fee
None
None
The performance data shown represent past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate so that investors' shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data cited.
Performance data do not reflect the deduction of the $25 annual account service fee that may be applied to certain accounts. If this fee was included, performance would be lower.
Closing price as of
This information is temporarily unavailable.
This chart can’t be displayed on mobile devices. For the best viewing experience, visit this page from your desktop or laptop.
as of 02/28/2025
Weighted equity exposures exclude any temporary cash investments and equity index futures. Some short-term fixed income securities are classified as cash and are excluded from the weighted bond exposures.
as of 02/28/2025
| Ticker | Holdings | Shares | Market value |
|---|---|---|---|
| 2330 | Taiwan Semiconductor Manufacturing Co. Ltd. | 48,724,873 | $1,486,157,021 |
| 700 | Tencent Holdings Ltd. | 12,566,904 | $773,449,030 |
| SAP | SAP SE | 2,225,879 | $617,683,894 |
| 9988 | Alibaba Group Holding Ltd. | 34,410,140 | $568,961,149 |
| NOVO B | Novo Nordisk A/S Class B | 6,268,562 | $568,662,638 |
| ASML | ASML Holding NV | 798,436 | $567,904,226 |
| NESN | Nestle SA | 5,218,637 | $503,773,463 |
| ROG | Roche Holding AG | 1,402,833 | $467,185,514 |
| AZN | AstraZeneca plc | 3,040,149 | $459,969,841 |
| NOVN | Novartis AG | 4,056,138 | $441,388,182 |
| Ticker | Holdings | Shares | Market value |
|---|---|---|---|
| 2330 | Taiwan Semiconductor Manufacturing Co. Ltd. | 48,724,873 | $1,486,157,021 |
| 700 | Tencent Holdings Ltd. | 12,566,904 | $773,449,030 |
| SAP | SAP SE | 2,225,879 | $617,683,894 |
| 9988 | Alibaba Group Holding Ltd. | 34,410,140 | $568,961,149 |
| NOVO B | Novo Nordisk A/S Class B | 6,268,562 | $568,662,638 |
| ASML | ASML Holding NV | 798,436 | $567,904,226 |
| NESN | Nestle SA | 5,218,637 | $503,773,463 |
| ROG | Roche Holding AG | 1,402,833 | $467,185,514 |
| AZN | AstraZeneca plc | 3,040,149 | $459,969,841 |
| NOVN | Novartis AG | 4,056,138 | $441,388,182 |
| Ticker | Holdings | Shares | Market value |
|---|---|---|---|
| 2330 | Taiwan Semiconductor Manufacturing Co. Ltd. | 48,724,873 | $1,486,157,021 |
| 700 | Tencent Holdings Ltd. | 12,566,904 | $773,449,030 |
| SAP | SAP SE | 2,225,879 | $617,683,894 |
| 9988 | Alibaba Group Holding Ltd. | 34,410,140 | $568,961,149 |
| NOVO B | Novo Nordisk A/S Class B | 6,268,562 | $568,662,638 |
| ASML | ASML Holding NV | 798,436 | $567,904,226 |
| NESN | Nestle SA | 5,218,637 | $503,773,463 |
| ROG | Roche Holding AG | 1,402,833 | $467,185,514 |
| AZN | AstraZeneca plc | 3,040,149 | $459,969,841 |
| NOVN | Novartis AG | 4,056,138 | $441,388,182 |
Realized gain
% of NAV
Unrealized gains of NAV
% of NAV
Fiscal year end
Distribution schedule
A fund's capital gains and losses can reveal the tax implications of holding a particular fund in a taxable account. This is true of both realized and unrealized capital gains and losses.
Learn about realized and unrealized gains and lossesA fund's capital gains and losses can reveal the tax implications of holding a particular fund in a taxable account. This is true of both realized and unrealized capital gains and losses.
Learn about realized and unrealized gains and lossesPerformance & fees
Most recent data available. © 2023 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; (3) does not constitute investment advice offered by Morningstar; and (4) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
© 2023 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Vanguard average mutual fund expense ratio: 0.09%. Industry average mutual fund expense ratio: 0.50%. All averages are asset-weighted. Industry average excludes Vanguard. Sources: Vanguard and Morningstar, Inc., as of December 31, 2023.
Total returns: Short-term total return information is provided only as a service. Historical performance—particularly short-term performance—is no guarantee of future returns. Price, yield, and return on an actual investment will fluctuate, and you may have a gain or loss when you sell. Average annual returns include changes in price and reinvestments of dividends and capital gains. Since-inception returns for less than 1 year and year-to-date returns aren't annualized. Index performance is provided as a benchmark but isn't illustrative of any particular investment. You can't invest in an index.
Standardized returns: To see quarterly fee-adjusted returns, refer to the Price & Performance details.
Expense ratios: Expense ratios are displayed on Overview. For investments that are less than 1 fiscal year old, expense ratios are estimated.
Risk: All investing is subject to risk, including the possible loss of the money you invest. Funds that concentrate on a relatively narrow market sector face the risk of higher share-price volatility. Investments in stocks or bonds issued by non-U.S. companies are subject to risks including country/regional risk and currency risk.